- Home
- IDYA vs MCRI Comparison
IDYA vs MCRI Comparison
Compare IDYA & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- MCRI
- Stock Information
- Founded
- IDYA 2015
- MCRI 1972
- Country
- IDYA United States
- MCRI United States
- Employees
- IDYA N/A
- MCRI N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- MCRI Hotels/Resorts
- Sector
- IDYA Health Care
- MCRI Consumer Discretionary
- Exchange
- IDYA Nasdaq
- MCRI Nasdaq
- Market Cap
- IDYA 2.3B
- MCRI 1.9B
- IPO Year
- IDYA 2019
- MCRI 1993
- Fundamental
- Price
- IDYA $31.60
- MCRI $89.70
- Analyst Decision
- IDYA Buy
- MCRI Hold
- Analyst Count
- IDYA 17
- MCRI 5
- Target Price
- IDYA $48.20
- MCRI $97.60
- AVG Volume (30 Days)
- IDYA 1.3M
- MCRI 88.7K
- Earning Date
- IDYA 11-04-2025
- MCRI 10-21-2025
- Dividend Yield
- IDYA N/A
- MCRI 1.35%
- EPS Growth
- IDYA N/A
- MCRI N/A
- EPS
- IDYA N/A
- MCRI 4.41
- Revenue
- IDYA $7,000,000.00
- MCRI $539,635,000.00
- Revenue This Year
- IDYA $90.17
- MCRI $6.99
- Revenue Next Year
- IDYA $219.42
- MCRI $3.72
- P/E Ratio
- IDYA N/A
- MCRI $20.35
- Revenue Growth
- IDYA N/A
- MCRI 4.61
- 52 Week Low
- IDYA $13.45
- MCRI $69.99
- 52 Week High
- IDYA $33.64
- MCRI $113.88
- Technical
- Relative Strength Index (RSI)
- IDYA 63.75
- MCRI 31.34
- Support Level
- IDYA $28.17
- MCRI $91.06
- Resistance Level
- IDYA $33.64
- MCRI $93.83
- Average True Range (ATR)
- IDYA 1.70
- MCRI 2.62
- MACD
- IDYA 0.33
- MCRI -0.56
- Stochastic Oscillator
- IDYA 72.58
- MCRI 15.51
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.